For­bion spot­lights late-stage plays, carves out new €250M growth fund

Hav­ing staked its rep on pick­ing out a mix of biotech in­vest­ment op­por­tu­ni­ties across the “build,” “en­able,” “growth” con­tin­u­um, For­bion is launch­ing its first fund ded­i­cat­ed to late-stage op­por­tu­ni­ties.

For­bion Growth Op­por­tu­ni­ties Fund’s first close brought in €185 mil­lion ($208 mil­lion). Ex­ist­ing in­vestors Pan­theon, KfW Cap­i­tal and the Eu­ro­pean In­vest­ment Fund came on board, joined by new back­ers Eli Lil­ly, Hori­zon Ther­a­peu­tics, Bel­gian Growth Fund and New Waves In­vest­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER